ArticleCancer imaging : the official publication of the International Cancer Imaging Society2026
Dynamic nomogram for predicting axillary lymph node metastasis in breast cancer based on MRI analysis and the platelet-to-lymphocyte ratio (PLR).
Article in Cancer imaging : the official publication of the International Cancer Imaging Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThis study aimed to develop a dynamic nomogram in which clinical indicators are integrated with magnetic resonance imaging (MRI) radiomics to predict axillary lymph node metastasis (ALNM) in patients with breast cancer.
methodsOur retrospective study included 221 pathologically confirmed patients with breast cancer. Radiomic features were extracted from dynamic contrast-enhanced MRI (DCE-MRI) and fat-suppressed T2-weighted imaging (FS-T2WI) datasets. After feature screening, a support vector machine (SVM) algorithm was employed to establish radiomic models and calculate radiomic scores. Clinical independent predictors were identified through univariate and multivariate logistic regression analyses. A nomogram was established on the basis of the radiomic scores obtained with the optimal SVM model and clinically independent predictors, and it was subsequently transformed into a dynamic nomogram. Model performance was evaluated by the receiver operating characteristic curve and area under the curve (AUC). Shapley additive explanation (SHAP) was applied to interpret the contribution of clinical predictors. Calibration and decision curves were employed to assess nomogram performance.
resultsThe platelet-to-lymphocyte ratio (PLR), breast imaging reporting and data system (BI-RADS) classification, and ALN status on MRI were identified as independent predictors of ALNM (all p < 0.05). SHAP analysis identified PLR as the top contributor. The clinical model developed with the three predictors achieved AUCs of 0.845 and 0.706 in the training and validation cohorts, respectively. Among the SVM models, the DCE-MRI and FS-T2WI fusion sequence model outperformed the single-sequence models, with AUCs of 0.868 and 0.875, respectively, in the training and validation cohorts. When clinical predictors were incorporated into the fusion sequence model, the nomogram achieved AUC values of 0.930 and 0.928 in the training and validation cohorts. Decision curve analysis demonstrated that the nomogram has significant clinical value.
conclusionsA nomogram model integrating MRI-derived radiomic scores, BI-RADS classification, ALN status, and PLR demonstrated good performance in predicting ALNM in patients with breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.